Decreased estrogen receptor-α expression in hippocampal neurons in relation to hyperphosphorylated tau in Alzheimer patients

被引:59
作者
Hu, XY
Qin, S
Lu, YP
Ravid, R
Swaab, DF
Zhou, HN [1 ]
机构
[1] Anhui Med Univ, Anhui Geriatr Inst, Affiliated Hosp 1, Hefei 230022, Peoples R China
[2] Univ Sci & Technol China, Dept Neurobiol, Sch Life Sci, Hefei 230026, Peoples R China
[3] Netherlands Inst Brain Res, NL-1105 AZ Amsterdam, Netherlands
基金
中国国家自然科学基金;
关键词
estrogen receptor-alpha; pretangle; hippocampus; Alzheimer's disease;
D O I
10.1007/s00401-003-0720-3
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Emerging evidence has demonstrated the neuroprotection of estrogen in Alzheimer's disease (AD). The hippocampus, an important target of estrogen action, is severely affected in the Alzheimer process. The aim of present study was to detect the distribution of estrogen receptor-alpha (ER-alpha) and the relationship between ER-alpha-containing neurons and the pretangles stained by Alz-50 in the hippocampus of AD patients. The results showed that more than half of hippocampal neurons expressed ER-alpha. The number of cytoplasmic ER-alpha-positive neurons was significantly decreased in the CA1 and CA2 subfields of AD hippocampus, but the ratio of these ER-alpha-expressing neurons to the nucleolated neuronal profiles stained by thionin was not different between the two groups. Interestingly, the number of nuclear ER-alpha-staining neurons was also markedly decreased in the CA1 and CA2 subfields of AD hippocampus, and the percentage of these nuclear staining neurons was also significantly decreased in the same subfields. Furthermore, some double-labeled neurons containing ER-alpha and Alz-50 were found in AD patients. However, in these double-labeled neurons, ER-a was only located in the cytoplasm. Thus, we hypothesize that the nuclear ER-alpha may play more important roles of neuroprotection during the process of AD.
引用
收藏
页码:213 / 220
页数:8
相关论文
共 50 条
[1]  
[Anonymous], 1997, Neurobiol Aging, V18, pS1
[2]   Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with Alzheimer's disease: results of a placebo-controlled, double-blind, pilot study [J].
Asthana, S ;
Craft, S ;
Baker, LD ;
Raskind, MA ;
Birnbaum, RS ;
Lofgreen, CP ;
Veith, RC ;
Plymate, SR .
PSYCHONEUROENDOCRINOLOGY, 1999, 24 (06) :657-677
[3]   PREVALENCE OF DEMENTIA AND PROBABLE SENILE DEMENTIA OF THE ALZHEIMER TYPE IN THE FRAMINGHAM-STUDY [J].
BACHMAN, DL ;
WOLF, PA ;
LINN, R ;
KNOEFEL, JE ;
COBB, J ;
BELANGER, A ;
DAGOSTINO, RB ;
WHITE, LR .
NEUROLOGY, 1992, 42 (01) :115-119
[4]   The role of estrogen in the treatment of Alzheimer's disease [J].
Birge, SJ .
NEUROLOGY, 1997, 48 (05) :S36-S41
[5]   CYTOPLASMIC ESTROGEN-RECEPTORS IN RAT-BRAIN - IMMUNOCYTOCHEMICAL EVIDENCE USING 3 ANTIBODIES WITH DISTINCT EPITOPES [J].
BLAUSTEIN, JD .
ENDOCRINOLOGY, 1992, 131 (03) :1336-1342
[6]  
Blurton-Jones MM, 1999, J COMP NEUROL, V405, P529, DOI 10.1002/(SICI)1096-9861(19990322)405:4<529::AID-CNE6>3.0.CO
[7]  
2-Y
[8]   Perimembrane localization of the estrogen receptor α protein in neuronal processes of cultured hippocampal neurons [J].
Clarke, CH ;
Norfleet, AM ;
Clarke, MSF ;
Watson, CS ;
Cunningham, KA ;
Thomas, ML .
NEUROENDOCRINOLOGY, 2000, 71 (01) :34-42
[9]   Cells containing immunoreactive estrogen receptor-α in the human basal forebrain [J].
Donahue, JE ;
Stopa, EG ;
Chorsky, RL ;
King, JC ;
Schipper, HM ;
Tobet, SA ;
Blaustein, JD ;
Reichlin, S .
BRAIN RESEARCH, 2000, 856 (1-2) :142-151
[10]   The Alzheimer's disease assessment scale: Patterns and predictors of baseline cognitive performance in multicenter Alzheimer's disease trials [J].
Doraiswamy, PM ;
Bieber, F ;
Kaiser, L ;
Krishnan, KR ;
ReuningScherer, J ;
Gulanski, B .
NEUROLOGY, 1997, 48 (06) :1511-1517